TEVA
Selected financial data by segment (unaudited) North America Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30 BiopharmaWatch Research Key Takeaway: Selected financial data by segment (unaudited)
North America Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30, March 31, 2017 (Unaudited, U.S.$ in millions) Revenues $ 12,141 $ 11,778 $ 2,689
BiopharmaWatch Analysis From our catalyst data and publicly available data · not financial advice Best trade, last catalyst
+92%
120-day peak, hindsight
Typical move
2.2%
average across 12 past catalysts
Lead asset
DR-5001
Phase 3 · Respiratory Tract Diseases
Full Press Release Details Selected financial data by segment (unaudited)
North America Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30, March 31, 2017 (Unaudited, U.S.$ in millions) Revenues $ 12,141 $ 11,778 $ 2,689 $ 3,043 $ 3,169 $ 3,240 Gross profit 7,509 8,567 1,538 1,833 2,058 2,080 R&D expenses 969 1,040 192 230 280 267 S&M expenses 1,475 1,525 317 325 392 441 G&A expenses 533 496 101 149 144 139 Other income (92 ) (30 ) (10 ) (1 ) (8 ) (73 ) Segment profit* $ 4,624 $ 5,536 $ 938 $ 1,130 $ 1,250 $ 1,306
Europe Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30, March 31, 2017 (Unaudited, U.S.$ in millions) Revenues $ 5,466 $ 4,969 $ 1,450 $ 1,380 $ 1,295 $ 1,341 Gross profit 2,910 2,722 763 721 692 734 R&D expenses 390 383 78 101 105 106 S&M expenses 1,153 1,304 289 289 296 279 G&A expenses 354 377 96 90 89 79 Other income (16 ) (9 ) (1 ) (17 ) 2 Segment profit* $ 1,029 $ 667 $ 301 $ 241 $ 219 $ 268
Growth Markets Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30, March 31, 2017 (Unaudited, U.S.$ in millions) Revenues $ 3,395 $ 4,015 $ 910 $ 882 $ 885 $ 718 Gross profit 1,433 1,816 390 351 400 292 R&D expenses 154 205 25 35 47 47 S&M expenses 672 759 169 158 187 158 G&A expenses 189 225 45 51 45 48 Other income (8 ) (10 ) (4 ) (3 ) (1 ) Segment profit* $ 426 $ 637 $ 155 $ 110 $ 121 $ 40
Tags: TEVA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare